Lepu Medical(SZ:300003) Haitong Securities International·2025-10-31 08:12Investment Rating - The report maintains an "Outperform" rating for the company [4][12][26]. Core Insights - The company has shown stable overall performance, with explosive growth in new products such as "童颜针" (Youth Needle) and "水光针" (Water Light Needle), driving rapid profit growth [1][4]. - In the first three quarters of 2025, the company achieved revenue of RMB 4.94 billion, a year-on-year increase of 3.20%, and a net profit attributable to shareholders of RMB 982 million, up 22.35% [4][12]. - The target price is set at RMB 20.29, based on a PE ratio of 35X for 2025, reflecting the company's stable growth and rapid expansion of new products [4][12]. Financial Summary - Total revenue for 2023 is projected at RMB 7.98 billion, with a decrease of 24.8% compared to the previous year. However, revenue is expected to grow by 10.1% in 2025 and continue to rise in subsequent years [3][5]. - Net profit attributable to shareholders is forecasted to be RMB 1.09 billion in 2025, a significant increase of 341.5% from 2024 [3][5]. - The company reported a net cash flow from operating activities of RMB 1.01 billion, reflecting a substantial increase of 139.37% [4][12]. Product Performance - In Q3 2025, the company generated revenue of RMB 1.57 billion, with specific products like "童颜针" and "水光针" contributing RMB 86.14 million for the first time [4][13]. - The cardiovascular intervention segment remains the largest revenue contributor, generating RMB 1.79 billion, up 7.45% year-on-year [4][15]. - The medical services and health management segment also showed growth, with revenue reaching RMB 796 million, an increase of 6.79% [4][15].